lecanemab-irmb
Eisai Seeks FDA Approval for Monthly IV Dosing of LEQEMBI for Alzheimer’s Disease Treatment
LEQEMBI, Eisai, FDA, Alzheimer’s disease, monthly IV dosing, subcutaneous autoinjector, lecanemab-irmb, Biogen
Actionable Insights Powered by AI
LEQEMBI, Eisai, FDA, Alzheimer’s disease, monthly IV dosing, subcutaneous autoinjector, lecanemab-irmb, Biogen